We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Approval is based on the SENSCIS study which showed Nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD).
Manufacturers of paracetamol tablets need to supply the minimum quantity but not less than their average supply of the past three months (January, February and March) in the domestic market.